HCPCS C9081 is officially defined as "Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." No tracked policy changes reference HCPCS C9081 yet. New payer updates are added daily, so check back soon or create a free alert to be notified the moment a change affects this code.
No tracked policy changes match this filter yet. New policies are added daily.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.